Observational studies, another defense of digoxin, CTO-PCI, BP measurement, and a possible revolution in cardiovascular protection are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
I. Observational Research
Yeh; Credibility in Observational Research https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064645
Hernan; Causal Language in Observational Research https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2018.304337
Wang; RCT Duplicate Initiative https://jamanetwork.com/journals/jama/fullarticle/2804067
II. Defense of Digoxin
Brophy; Beta Blockers, Digoxin, or Both https://doi.org/10.1016/j.cjca.2023.06.009
Dorian editorial https://doi.org/10.1016/j.cjca.2023.07.013
Ziff Digoxin Meta-analysis https://www.bmj.com/content/351/bmj.h4451.long
DIG trial https://www.nejm.org/doi/full/10.1056/nejm199702203360801
Davila Analysis of DIG Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801940/
Kotecha Meta-analysis of Beta Blockers https://pubmed.ncbi.nlm.nih.gov/25193873/
RATE-AF https://jamanetwork.com/journals/jama/fullarticle/2774407
III. CTO-PCI
PCI of Chronic Total Occlusions Improves Angina, Quality of Life in Trials https://www.medscape.com/viewarticle/994739
JAMA Network Open Meta-analysis
IV. BP Measurement
One Size Doesn’t Fit All in Blood Pressure Measurement https://www.medscape.com/viewarticle/995216
Ishigami Blood Pressure Measurement Comparison
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2807853
V. GLP-1 SELECT Trial
Semaglutide Cuts Cardiovascular Events in Landmark Trial
https://www.medscape.com/viewarticle/995270
SELECT Protocol Paper
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]